Wednesday - June 10, 2026
Sanofi's Cenrifki (tolebrutinib) Recommended for EU Approval by the CHMP to Treat Secondary Progressive Multiple Sclerosis Without Relapses
April 25, 2026
PARIS, France, April 25 (TNSrpt) -- Sanofi, a life sciences company, issued the following news release:

* * *

Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses

* Recommendation based on the HERCULES phase 3 study which demonstrated that brain-penetrant Cenrifki (tolebrutinib) significantly delayed the onset of disability progression in non-relapsing SPMS

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products